Veda N Giri, MD

I believe that patients receive the best care by having a comprehensive evaluation in a receptive and understanding environment. With my background in medical oncology and translational cancer research, I am able to provide a unique experience to my patients with regard to the evaluation and treatment of cancer. In addition, I have a special interest in genetic and familial risk for prostate cancer.

I joined the staff of Fox Chase in 2004. Since that time, I have been named the director of Prostate Risk Assessment. This service offers genetic and familial risk evaluation for men with prostate cancer (Prostate Cancer Risk Consult clinic) and early detection options for men at high risk for developing prostate cancer (Prostate Cancer Risk Assessment Program). Therefore, we offer comprehensive evaluation and management for prostate cancer risk, detection, and prevention.

I serve on the National Institutes of Health Prostate Cancer Genetics PDQ Editorial Board as well as the National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection Panel. At Fox Chase, I am an active member of the IRB (Institutional Review Board) as well as the Executive Steering Committee, the Risk Assessment Program, and the Data and Safety Monitoring Committee for Extramural Research.

I have received a five-year career development grant from the Department of Defense to study genetic variants in prostate cancer risk. In addition, I have a grant from the National Cancer Institute to study genetic markers of early onset prostate cancer. In the laboratory, I perform ongoing research into the genetic, molecular and proteomic pathways involved in prostate cancer susceptibility. I am also involved in providing prostate cancer risk assessment services to underserved men in the community through a partnership with the department of Health Communications and Health Disparities at Fox Chase Cancer Center.